-+ 0.00%
-+ 0.00%
-+ 0.00%

Soligenix says ThermoVax platform supports rapid development of thermostable Bundibugyo virus vaccine

PUBT·05/26/2026 11:30:51
Listen to the news
Soligenix says ThermoVax platform supports rapid development of thermostable Bundibugyo virus vaccine
  • Soligenix flagged the Congo Bundibugyo virus outbreak as a trigger for new vaccine formulation work using its ThermoVax platform.
  • Prior bivalent and trivalent protein-subunit filovirus vaccines showed thermostability, immunogenicity, durable efficacy, up to 100% protection in non-human primates.
  • Earlier lab work indicated compatibility of a key Bundibugyo antigen, positioning the program for rapid development of a thermostable subunit vaccine.
  • Development pace tied to funding; approach targets ambient-temperature shipping, single-vial reconstitution, strategic stockpiles, outbreak response, booster use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260730PR_NEWS_USPR_____PH66545) on May 26, 2026, and is solely responsible for the information contained therein.